StreetInsider.com News Articles

Form DEFA14A Tenaya Therapeutics,

Fri, 23 Oct 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20261023/27228562.html

Form DEF 14A Tenaya Therapeutics, For: Dec 09

Fri, 23 Oct 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20261023/27228411.html

Form PRE 14A Tenaya Therapeutics, For: Dec 09

Tue, 13 Oct 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20261013/27181658.html

FDA grants RMAT designation to Tenaya's TN-401 heart gene therapy

Mon, 14 Sep 2026 08:32:52 -0400

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TN-401, the company's gene therapy candidate for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).

The designation was supported by interim data from the RIDGE-1 Phase 1b/2 clinical trial, which showed reductions in daily rates of premature ventricular contractions (PVCs) and non-sustained ventricular tachycardias (NSVTs), along with a favorable tolerability profile. That data was previously presented at the American Society for Gene and Cell Therapy Annual Meeting in May 2026.

TN-401 also holds Orphan Drug and Fast Track designations

FDA grants RMAT designation to Tenaya's TN-401 heart gene therapy

Mon, 14 Sep 2026 08:32:52 -0400

TN-401 also holds Orphan Drug and Fast Track designations

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Mon, 14 Sep 2026 08:30:00 -0400

RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden

Additional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TN-401, Tenaya’s gene therapy candidate for

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Mon, 14 Sep 2026 08:30:00 -0400

RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden

Additional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026

Form 4 Tenaya Therapeutics, For: Sep 10 Filed by: Ali Faraz

Fri, 11 Sep 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260911/27053962.html

Form 4 Tenaya Therapeutics, For: Sep 10 Filed by: Tingley Whittemore

Fri, 11 Sep 2026 20:10:00 -0400

si-local-file:///var/storage/secattach/20260911/27053961.html

Form SCHEDULE 13G Tenaya Therapeutics, Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Mon, 24 Aug 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260824/26969329.html

Form SCHEDULE 13G Tenaya Therapeutics, Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Mon, 24 Aug 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260824/26969329.html

Form 4 Tenaya Therapeutics, For: Aug 17 Filed by: Ali Faraz

Mon, 17 Aug 2026 20:50:00 -0400

si-local-file:///var/storage/secattach/20260817/26939356.html

Form 4 Tenaya Therapeutics, For: Aug 17 Filed by: Ali Faraz

Mon, 17 Aug 2026 20:50:00 -0400

si-local-file:///var/storage/secattach/20260817/26939356.html

Form 4 Tenaya Therapeutics, For: Aug 17 Filed by: Tingley Whittemore

Mon, 17 Aug 2026 20:49:00 -0400

si-local-file:///var/storage/secattach/20260817/26939355.html

Form 4 Tenaya Therapeutics, For: Aug 17 Filed by: Tingley Whittemore

Mon, 17 Aug 2026 20:49:00 -0400

si-local-file:///var/storage/secattach/20260817/26939355.html

Form 144 Tenaya Therapeutics, Filed by: Ali Faraz

Mon, 17 Aug 2026 20:46:00 -0400

si-local-file:///var/storage/secattach/20260817/26939353.html

Form 144 Tenaya Therapeutics, Filed by: Ali Faraz

Mon, 17 Aug 2026 20:46:00 -0400

si-local-file:///var/storage/secattach/20260817/26939353.html

Form 144 Tenaya Therapeutics, Filed by: Tingley Whittemore

Mon, 17 Aug 2026 20:45:00 -0400

si-local-file:///var/storage/secattach/20260817/26939352.html

Form 144 Tenaya Therapeutics, Filed by: Tingley Whittemore

Mon, 17 Aug 2026 20:45:00 -0400

si-local-file:///var/storage/secattach/20260817/26939352.html

Tenaya Therapeutics, Inc. (TNYA) Misses Q2 EPS by 14c

Wed, 05 Aug 2026 18:22:24 -0400

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported Q2 EPS of ($0.20), $0.14 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $1.11 million versus the consensus estimate of $2.5 million.

For earnings history and earnings-related data on Tenaya Therapeutics, Inc. (TNYA) click here.

Form S-8 Tenaya Therapeutics,

Wed, 05 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260805/26874885.html

Form S-8 Tenaya Therapeutics,

Wed, 05 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260805/26874885.html

Form 10-Q Tenaya Therapeutics, For: Jun 30

Wed, 05 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260805/26874555.html

Form 10-Q Tenaya Therapeutics, For: Jun 30

Wed, 05 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260805/26874555.html

Form 8-K Tenaya Therapeutics, For: Aug 05

Wed, 05 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26874261.html